Adar Poonawalla

RDIF and Serum Institute of India, the world's largest vaccine manufacturer by volume, to start production of Sputnik vaccine at Company's facilities in September

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Medicine, Health care, Adenoviridae, COVID-19 vaccines, Clinical trials, Vaccine controversies, COVID-19 pandemic in Russia, Serum Institute of India, Sputnik V COVID-19 vaccine, Adar Poonawalla, Kirill Dmitriev

SII is the world's largest company in terms of COVID vaccines production with over 500 million doses manufactured.

Key Points: 
  • SII is the world's largest company in terms of COVID vaccines production with over 500 million doses manufactured.
  • The first batch of Sputnik vaccine is expected to be produced at SII's facilities in September.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:
    "RDIF is delighted to cooperate with Serum Institute of India, the world's largest vaccine manufacturer.
  • Adar Poonawalla, CEO of Serum Institute of India,commented:
    "I am delighted to partner with RDIF to manufacture the Sputnik vaccine.

Serum Institute Selects ABEC for Large-Scale, Single-Use COVID-19 Vaccine Manufacturing

Retrieved on: 
Wednesday, September 30, 2020
Women, Other Health, Seniors, Teens, Parenting, Pharmaceutical, MEN, Children, Family, Infectious diseases, Hospitals, Consumer, Nursing, Clinical trials, Medical Supplies, FDA, Biotechnology, Health, Pharmaceutical companies, Health care, Medical specialties, Serum Institute of India, Vaccine, COVID-19 vaccine, Single-use bioreactor, Novavax, Adar Poonawalla

ABEC , a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is supporting Serum Institute of India Pvt.

Key Points: 
  • ABEC , a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is supporting Serum Institute of India Pvt.
  • Ltd. (SIIPL) in Pune, India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax COVID-19 vaccine candidate, NVXCoV2373.
  • Serum Institute, the worlds largest vaccine manufacturer by number of doses, will utilize ABECs single-use technologies to advance a global supply of NVXCoV2373 throughout India and low- and middle-income countries.
  • Serum Institutes new facility will be the largest single-use bioreactor-based vaccine manufacturing line in the world.

Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate

Retrieved on: 
Tuesday, September 22, 2020
Medical specialties, Economy of India, Health care, Serum Institute of India, Vaccines, Vaccine, Cyrus S. Poonawalla, RTT, Adar Poonawalla, Medical research

FARMINGDALE, N.Y., Sept. 22, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced that the Serum Institute of India has begun manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • FARMINGDALE, N.Y., Sept. 22, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced that the Serum Institute of India has begun manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.
  • Codagenix, backed by investors Adjuvant Capital and TopSpin Partners, is collaborating with the Serum Institute of India, the world's largest vaccine maker by number of doses produced, to develop CDX-005.
  • It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute.
  • Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices.

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

Retrieved on: 
Tuesday, September 8, 2020
Medical specialties, Vaccines, Medicine, Vaccination, Vaccine, Virology, Virus-like particle, Adar Poonawalla, RTT, COVID-19 vaccine, H5N1 clinical trials

SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19.

Key Points: 
  • SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19.
  • HBsAg VLPs are a licensed vaccine with excellent safety and immunogenicity data in humans and which are currently manufactured to billions of doses.
  • SpyBiotech has exclusive rights from the University of Oxford to apply, commercialise and sub-license the plug and display technology for vaccine development.
  • Adar Poonawalla, Chief Executive Officer of SIIPL, added: We are very excited about the collaboration with SpyBiotech to work on this novel vaccine for COVID-19.

Novavax and Serum Institute of India Announce Development and Commercial Collaboration

Retrieved on: 
Thursday, August 6, 2020
Medical specialties, Health care, Pharmaceutical companies, Vaccines, Novavax, Malaria, Adar Poonawalla, Vaccine, Serum Institute of India, Malaria vaccine, COVID-19 vaccine

As the worlds largest vaccine manufacturer in terms of doses delivered, Serum Institute is the ideal partner to advance NVXCoV2373 throughout India and the LMIC countries.

Key Points: 
  • As the worlds largest vaccine manufacturer in terms of doses delivered, Serum Institute is the ideal partner to advance NVXCoV2373 throughout India and the LMIC countries.
  • For LMICs and India, Novavax and SIIPL are partnering on clinical development, co-formulation, filling and finishing and commercialization of NVX-CoV2373.
  • Novavax will provide to SIIPL both vaccine antigen and MatrixM adjuvant, and Novavax and SIIPL are in discussions to have SIIPL manufacture vaccine antigen in India.
  • Given our experience with Novavax on the development of a malaria vaccine, we know the power of their vaccine technologies, said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Retrieved on: 
Wednesday, March 11, 2020
Infectious diseases, Medical specialties, Medicine, Malaria, Vaccines, Novavax, Hypothetical technology, Malaria vaccine, Adar Poonawalla, Vaccine, Plasmodium falciparum, Serum Institute of India

SII licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum-induced malaria disease, from the Jenner Institute at Oxford University in 2017.

Key Points: 
  • SII licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum-induced malaria disease, from the Jenner Institute at Oxford University in 2017.
  • Matrix-M will be manufactured and supplied to SII by Novavax AB, a wholly-owned subsidiary of Novavax based in Uppsala, Sweden.
  • He commented, It has proven very challenging to develop a vaccine against malaria and many different approaches have been tested.
  • Novavax next-generation adjuvant, Matrix-M, is an impressive and critical component in this much-needed malaria vaccine, said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.